Blood Substitutes (Crosslinked Hemoglobin)

Study Highlights Need for Selecting Optimal Dose

Published in Blood Weekly, March 31st, 1997

In a recent dose-response study conducted in rats, cardiovascular effects varied unpredictably according to dosages of diaspirin crosslinked hemoglobin (DCLHb) .

DCLHb, a hemoglobin-based blood substitute developed by Baxter Healthcare Corporation, USA, has been found to increase mean arterial pressure (MAP) in a dose limiting manner, noted Abhijit Barve, the University of Illinois at Chicago, Chicago, Illinois, and colleagues.

Barve et al. performed a study to determine dose-dependent effects of DCLHb on systemic hemodynamics and regional blood circulation ("Dose Response Effect of Diaspirin Crosslinked Hemoglobin (DCLHb) on Systemic Hemodynamics...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry